Attached files

file filename
EX-99.1 - EX-99.1 - HERON THERAPEUTICS, INC. /DE/exhibit1.htm






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   July 17, 2015

Heron Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-33221 94-2875566
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
123 Saginaw Drive, Redwood City, California   94063
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   650-366-2626

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On July 20, 2015, Heron Therapeutics, Inc. (the "Company") issued a press release announcing that it has resubmitted its New Drug Application for SUSTOL® (granisetron) Injection, extended release, for the prevention of acute and delayed chemotherapy-induced nausea and vomiting, to the U.S. Food and Drug Administration, as described in the press release furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No./ Description

99.1 Press Release, dated July 20, 2015


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Heron Therapeutics, Inc.
July 21, 2015   By:   /s/ Esme C. Smith
        Name: Esme C. Smith
        Title: VP, General Counsel & Secretary

Exhibit Index

Exhibit No.   Description

  Press Release dated July 20, 2015